A phase 4 study found severe asthma can be controlled using biologic therapies, without the addition of high-dose inhaled steroids. Among a cohort of patients with severe asthma using the biologic ...

A new study has found that using biologic therapy to reduce lung inflammation enabled 92% of people with severe asthma to reduce their dose of daily inhaled steroid without exacerbating their symptoms ...

For patients with severe eosinophilic asthma controlled on bevacizumab, tapering of inhaled corticosteroids (ICS) is feasible and is not associated with worse asthma control, according to a study ...

Most patients with severe asthma who were treated with the biologic therapy benralizumab were able to reduce their dose of inhaled corticosteroid (ICS), and more than half could stop steroid use ...

Please provide your email address to receive an email when new articles are posted on . 96% of patients maintained reductions through 48 weeks. 91% of patients had no exacerbations while tapering ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window MILAN -- ...

WASHINGTON -- Adding dupilumab (Dupixent) to a medium-dose inhaled corticosteroid (ICS) routine helped lower asthma exacerbations and improved both lung function and asthma control, according to a ...

Inhaled cortical steroids (ICS) can help patients manage asthma symptoms, and recent updates to asthma treatment guidelines have expanded recommended, low-dose treatment. But concerns persist that ICS ...

Please provide your email address to receive an email when new articles are posted on . Side effects were reported as early as 1953. The Joint Task Force on Practice Parameters conducted a review of ...